Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report analysing the European generic drug market.
“European Generic Drug Market Potential The Emergence of Generic Drug Biologics” reports that the use of generic medicines has allowed patients to access safe, effective, high-quality medicines at 20%-80% of the price of branded originator medicines.
In this way, generic medicines are supporting the sustainability of health care provision and contribute to controlling pharmaceutical expenditure. Competition from generic medicines is also inciting originator companies to develop innovative medicines and reduce prices of off patent originator medicines, thus generating additional savings to patients.
The 93 page report shows that in recent years, the European generic drugs markets have experienced dramatic changes. The business environment has become significantly more complex, and generic pharmaceutical companies are becoming increasingly international. To excel, companies must seek out the best conditions for developing, manufacturing and marketing their products. And they must work with governments to create this environment.
Regulatory policies governing the European generics market and the pharmaceutical market in Europe are also discussed, including supply side and demand side policies, along with market entry policies for generic medicines, policies governing the pricing of generic medicines, and others. Following all this is a country-wide analysis of the leading European generics markets. Profiles of the major companies actively competing in this industry are included in the report as well.
“European Generic Drug Market Potential The Emergence of Generic Drug Biologics”” is available from Piribo. For more information go to:
http://www.piribo.com/
Piribo product ID:PRC00005
